ABBV AbbVie Inc: Bathi saben saham sajrone rolas wulan pungkasan

The YoY EPS change on a rolling 12-month basis demonstrates the resilience of the biopharmaceutical behemoth AbbVie Inc. (ABBV), which relies on patent-protected oncology and immunology developments. Business efficiency is based on clinical trial results and government price regulation, while 338.50 expresses the metric's value today. The decline in Humira revenues due to biosimilars is partially offset by new products, mitigating regulatory risks.
AbbVie Corp. - rincian analitis lan metrik utama (ABBV)

This indicator captures the percentage change in earnings per share within a rolling annual window. By analyzing current EPS YoY TTM trends, investors can track the business scaling speed between official reports. The metric is calculated as the difference between the current and previous twelve-month EPS values. For AbbVie Inc. (ABBV), this growth confirms the effectiveness of its patent strategy and its ability to maintain pricing power against generics.